Abstract The emergence of SARS-CoV-2 variants of concern (VoCs) has exacerbated the COVID-19 pandemic. Currently available monoclonal antibodies and vaccines appear to have reduced efficacy against some of these VoCs. Antivirals targeting conserved proteins of SARS-CoV-2 are unlikely to be affected by mutations arising in VoCs and should therefore be effective against emerging variants. We here investigate the efficacy of molnupiravir, currently in phase 2 clinical trials, in hamsters infected with Wuhan strain or B.1.1.7 and B.1.351 variants. Molnupiravir proved to be effective against infections with each of the variants and therefore may have potential combating current and future emerging VoCs.
All Keywords
【저자키워드】 SARS-CoV-2, coronavirus, antivirals, molnupiravir, VoC, hamsters, B.1.351, breath, 【초록키워드】 Efficacy, Vaccine, Mutation, molnupiravir, hamsters, B.1.351, Phase 2, COVID-19 pandemic, monoclonal antibody, variant, SARS-CoV-2 variant, Infection, clinical trials, monoclonal antibodies, variants, Protein, SARS-CoV-2 variants, B.1.1.7, VOCs, hamster, B.1.351 variants, phase 2 clinical trials, Wuhan strain, effective, combating, affected, conserved, exacerbated, unlikely, reduced, arising, 【제목키워드】 molnupiravir, Model, hamster, concern,
【저자키워드】 SARS-CoV-2, coronavirus, antivirals, molnupiravir, VoC, hamsters, B.1.351, breath, 【초록키워드】 Efficacy, Vaccine, Mutation, molnupiravir, hamsters, B.1.351, Phase 2, COVID-19 pandemic, monoclonal antibody, variant, SARS-CoV-2 variant, Infection, clinical trials, monoclonal antibodies, variants, Protein, SARS-CoV-2 variants, B.1.1.7, VOCs, hamster, B.1.351 variants, phase 2 clinical trials, Wuhan strain, effective, combating, affected, conserved, exacerbated, unlikely, reduced, arising, 【제목키워드】 molnupiravir, Model, hamster, concern,
초록 SARS-CoV-2 우려 변종(VoC)의 출현은 COVID-19 대유행을 악화시켰습니다. 현재 사용 가능한 단일 클론 항체 및 백신은 이러한 VoC 중 일부에 대한 효능이 감소된 것으로 보입니다. SARS-CoV-2의 보존된 단백질을 표적으로 하는 항바이러스제는 VoC에서 발생하는 돌연변이에 의해 영향을 받지 않을 것이므로 새로운 변이체에 대해 효과적이어야 합니다. 우리는 여기에서 우한 균주 또는 B.1.1.7 및 B.1.351 변이체에 감염된 햄스터에서 현재 임상 2상 시험 중인 몰누피라비르의 효능을 조사합니다. Molnupiravir는 각 변이체의 감염에 효과적인 것으로 입증되었으므로 현재 및 미래에 출현하는 VoC에 잠재적으로 대처할 수 있습니다.